|Day Low/High||3.12 / 3.48|
|52 Wk Low/High||1.65 / 5.05|
We added to several positions on weakness during a challenging last week for the stock market.
We exited one position and added to another as volatility returned to the stock market last week.
It was a mixed week for the portfolio as we trimmed one position and added to the Bullpen.
Last week, we closed a position for a large gain and used some of the proceeds to start a small stake in a fracking and desalination name.
Despite a shortened trading week, we made a series of moves, including initiating a position in GSV Capital.
During a quiet week for the market, we added to two positions and trimmed three others.
We will buy more AcelRx Pharmaceuticals and sell shares of Inovio Pharmaceuticals as we close out 2017.
During another busy week, we rang the register and exited our position in Amplify, trimmed another name twice and scaled into a recent addition.
Last week was a busy one for the portfolio, as we made a number of trades and saw outsized gains in several positions.
We bought into some tech names last week as a rotation occurred in the sector.
For the second week in a row, we initiated a new position, this time in a security tech name.
We initiated a new position for the portfolio during the shortened holiday trading week.
We exited three biotech/pharma positions and added to two other holdings during a busy week for the portfolio.
We exited two positions today following a tough week for small-cap stocks.
Earnings analysis on four stocks -- and we are increasing our ACRX position on this weakness.
Last week, we increased our holdings in one position and added 2 Bullpen names.
We used price declines to scale into several holdings as small-caps underperformed the overall market.
Keep a close eye on this one, and establish a stop-loss order at or around $9.50.
This week brings earnings from 5 portfolio holdings as the market continues to shrug off potential negatives.
We have to purchase some AcelRx Pharmaceuticals to take advantage of these prices.
We took some profits and added a Bullpen name, among other moves, during a rough week for a few portfolio names.
We'll sell some AcelRx Pharmaceuticals and buy more Hudson Technologies.
We added to one name during a stellar week for the majority of the portfolio.
We took a healthy profit trimming one name and added to three other positions last week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.